Objective: To determine whether plasma homocysteine (Hcy) levels are associated with clinical characteristics, neuropsychological and psychiatric manifestations and cardiovascular comorbidity in patients with Parkinson disease (PD).
1,2 Their pathogenesis in PD is multifactorial. Elevated levels of homocysteine (Hcy), a sulfurcontaining amino acid that occupies a central location in the metabolic pathways of thiol compounds, were shown in epidemiological and experimental studies to be linked with several conditions associated with vascular pathology including coronary artery disease, vascular dementia, and ischemic stroke.
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Neurodegenerative processes have also been linked to elevated Hcy, including cognitive decline and Alzheimer disease. 6Y9 Moreover, genetic and clinical data suggest roles for folate deficiency and Hcy in the pathogenesis of some psychiatric disorders such as depression and schizophrenia. 10, 11 Plasma Hcy levels are elevated in patients with PD treated with L-dopa, resulting from the increased production of Sadenosylhomocysteine during the metabolism of L-dopa by catechol-O-methyltransferase. The clinical significance of L-dopaYinduced elevation of Hcy in PD on vascular disease, the disease course, or the development of the cognitive and psychiatric complications is not known. The aim of the current study was to examine the hypothesis that elevated plasma Hcy in PD is associated with measures of progression of PD, cognitive and neuropsychiatric complications, increased carotid intima-media thickness, and cardiovascular comorbidity.
PATIENTS AND METHODS
Consecutive patients with PD were prospectively recruited between September 2003 and January 2004 from the Movement Disorders Clinic and the Neurology Service at Sheba Medical Center. All the patients were diagnosed with idiopathic PD according to the UK bank criteria. The local ethics committee approved the study protocol, and all the patients had to give their informed consent before their inclusion in the study. Exclusion criteria included patients that are not fluent Hebrew speakers or having other central nervous system disorders (eg, normotensive hydrocephalus and brain tumor), psychiatric disorders (eg, major depression and schizophrenia), and prominent cerebrovascular disease and patients that had functional neurosurgical procedures for PD.
All the patients underwent systematic assessments of demographics, vascular risk factors, atherothrombotic manifestations (stroke, transient ischemic attack, ischemic heart disease, and peripheral vascular disease). Parkinson disease duration, predominant manifestations, presence of motor complications, types of medications, and drug regimen including dose and duration of L-dopa treatment were recorded. The physical status was measured using the Unified Parkinson's Disease Rating Scale (UPDRS) part III (the motor scale), in the ''on'' condition in patients experiencing motor fluctuations, and the Hoehn and Yahr scale, both ''on'' and ''off'' in patients experiencing motor fluctuations.
Neuropsychiatric disturbances were evaluated using the Beck Depression Inventory, 17 an Apathy Scale for PD, and the Parkinson Psychosis Rating Scale. 18 Patients were asked about having had hallucinations or delusions and presence of visual impairment. Sleep disturbances and daily somnolence were also documented. The global cognitive functioning was assessed using the Mini-Mental Status Examination. 19 Attention was assessed using the digit span forward and backward tests, 20 the Trail-making test (parts A and B), and the number-cancellation test. 21 Verbal memory was examined using the Hebrew version of ReyYauditory verbal learning test (the immediate recall, leaning, and delayed parts).
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Visual memory was assessed using the ReyOsterrieth complex figure test, including copy, immediate, and delayed parts. 21 The frontal lobe functioning was examined using the Frontal Assessment Battery 23 and tests for phonemic and semantic word fluency. 21 In the morning, after 12 hours of fasting, blood samples were drawn from a peripheral vein in plastic vacuum tubes containing EDTA. Within 10 minutes, the samples were centrifuged for 15 minutes, 300g at 10-C, and plasma was stored at j20-C. The Hcy levels were measured within 3 months using an automated high-performance liquid chromatography method with reverse phase separation and fluorescent detection, using NaBH4/monobromobimane reduction followed by monobromobimane derivation. A laboratory technician, who was blinded to any clinical data, performed all the tests.
For carotid ultrasound examination, common carotid artery intima-media thickness (IMT), a measure of atherosclerosis, was measured at the far wall of both common carotid arteries using an ATL ultrasound and dedicated software for image acquisition, semiautomatic measurements, and storage (M'Ath-Std, Metris, France).
Statistical Method
Patients were stratified into 3 groups by tertiles of Hcy level (first tertile, G12.5 2mol/L; second tertile, 12.5Y16.7 2mol/L; and third tertile, 916.7 2mol/L). Mean values of the quantitative variables were compared among the groups using 1-way analysis of variance or Kruskal-Wallis test according to their distribution. With regard to the analyses of cognitive function, a general linear model of analysis of variance was used to obtain multivariable-adjusted mean differences in scores among those with different levels of Hcy. To control for confounding in the model, we included, in addition to the Hcy level, the following variables: age and time duration of PD as continuous covariates and sex as a categorical covariate. Significant levels were set at P G 0.05. All statistical analyses were performed with statistical software (SPSS, version 12.0).
RESULTS
Seventy-two patients with PD (46 men and 26 women) were included. Their mean age was 68.7 T 11.6 years (range, 42Y96 years), and the mean PD duration was 7.0 T 4.7 years (range, 0.5Y18 years). Their characteristics are shown in Table 1 . The average plasma Hcy concentration was 16.4 T 7.8 2mol/L (range, 6.9Y45.1 2mol/L). Twenty-eight patients (38.9%) had elevated Hcy (Hcy levels, 915.0 2mol/L); all except for one were among the patients treated with L-dopa. The average Hcy level tended to be higher among patients treated with L-dopa (n = 62) than among untreated patients (n = 10) (17.0 T 8.1 2mol/L vs. 12.3 T 3.4 2mol/L; P = 0.068). Comparisons of the Hcy level according to L-dopa dose (Fig. 1 ) did not demonstrate a dose effect of L-dopa on Hcy level. An association was found between L-dopa treatment duration and the level of Hcy (P = 0.036).
Hcy levels did not correlate with the age of the patients. We could not demonstrate significant associations between Hcy levels and disease severity according to motor section of the UPDRS. We did find a positive association with disease duration (P = 0.003; also seen when analysis was performed for only the 62 patients treated with L-dopa) ( Table 2 ). This could account for the association of Hcy level with L-dopa treatment duration. The Hcy levels were not associated with vascular comorbidity such as coronary heart disease or with history of cerebrovascular disease, such as stroke or transient ischemic attack (data not shown in tables). No significant associations were identified between Hcy levels and the presence or history of depression, use of antidepressants, hallucinations, or use of antipsychotics or the presence of intellectual decline according to the part 1 of UPDRS (P 9 0.05 for all). Using the KruskalWallis test for comparison of 3 or more unmatched groups, we found no association between the Hcy level and Hohen and Yahr stages in the off and in the on states. No significant correlations were found between Hcy levels and any of the neuropsychological or psychiatric tests, including psychiatric and behavioral features, attention, verbal memory, frontal lobe function, or global cognitive function (Table 2) .
Among the patients undergoing assessment of the carotid IMT (n = 45), the average IMT of both common carotid arteries was 0.80 T 0.17 mm. Carotid IMT did not differ between patients with normal Hcy (n = 24; average, 0.79 T 0.17 mm) and those with elevated Hcy (n = 19; average, 0.81 T 0.17 mm). Carotid IMT correlated with the age of the patients (r = 0.55, P G 0.001) but did not correlate with any PD-related factors such as disease duration or severity or with measures of neuropsychiatric complications. Comparing the average IMT of the patients in the 3 Hcy tertiles, correcting for age, sex, and disease duration, yielded similar results.
DISCUSSION
Our main findings are that elevated concentrations of plasma Hcy were common (39%) among PD patients and were associated with the use of L-dopa, but plasma Hcy was not associated with neuropsychological complications (depression, dementia, frontal-type cognitive decline, or psychosis), enhanced disease severity, carotid IMT, or vascular comorbidity in our cohort of PD patients.
It has been previously established that L-dopa treatment, rather than the disease itself, is associated with elevated Hcy, and the metabolic pathways underlying this phenomenon are well documented. The MTHFR genotype and vitamin status have minor contributory effects to Hcy levels as well. 12, 24, 25 To date, there is limited evidence that L-dopaYinduced hyperhomocystinemia has any detrimental effects on PD patients. Elevated plasma Hcy is, however, well known to serve as a marker for vascular diseases 3, 4 and is associated with carotid IMT. 6, 24, 26 One cross-sectional study 27 found that L-dopaYassociated Hcy elevations were associated with a 1.7-fold increased prevalence of coronary artery disease, and another 28 reported its association with hypertrophy of the carotid intima-media complex. Plasma Hcy levels among our PD cohort were not associated with carotid IMT nor with prevalent vascular comorbidity. If L-dopaYinduced hyperhomocystinemia is a causal risk factor for vascular complications in PD, then one would expect epidemiological evidence of greater Hcy-associated diseases in PD patients. There is, however, no convincing data showing that cardiovascular disease or stroke is more prevalent in PD than in controls. 29, 30 Elevated Hcy levels have been identified as risk factors for cognitive decline and Alzheimer disease 6Y9 and may be linked to the pathogenesis of some psychiatric disorders such as depression and schizophrenia. 10, 11 The relative risk of developing dementia in PD is 4 to 6 times that of an age-matched population, but not all the mechanisms underlying it are elucidated. 5 In a recent study, mood and cognition outcomes were worse in PD patients with elevated Hcy levels, although the physical status was not significantly worse. 14 In our study, we did not find an effect of elevated Hcy on any of the neuropsychological complications of PD (depression, dementia, frontal-type cognitive decline, or psychosis). Also, we could not demonstrate any association between Hcy levels and measures of disease severity. The lack of any significant associations in our PD cohort between elevated Hcy levels and neuropsychological complications, enhanced disease severity, carotid IMT, or vascular comorbidity may potentially be caused by limited statistical power and type II error. The absence of any apparent effect, however, argues against any major detrimental effect. Because of the high public health implications of potentially preventing a reversible cause for PD-related complications, but potential hazards of unproven interventions, this hypothesis should be further explored in large prospective cohort studies and randomized clinical trials.
